Lantern Pharma (NASDAQ: LTRN) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application covering methods of selecting and treating patients with ovarian, primary liver, kidney and thyroid cancers using its investigational therapy LP-184 (zirdafulven) based on a three-gene biomarker signature. The allowed claims cover the use of elevated expression of PTGR1, PTPN14 and ASPH to identify patients who may benefit from treatment with LP-184. This milestone underscores the company’s progress in precision oncology and expands its intellectual property portfolio.
The company’s RADR artificial intelligence platform was instrumental in identifying the biomarker signature, supporting the development of a precision medicine approach for LP-184. In its Phase 1a trial, Lantern reported a 45% disease control rate among patients treated at or above the effective therapeutic dose. The company plans to advance LP-184 into multiple Phase 1b/2 precision oncology studies during 2026 while continuing to expand its intellectual property portfolio.
This patent allowance is significant because it validates the use of AI-driven biomarker discovery to guide patient selection, potentially increasing treatment efficacy and reducing unnecessary side effects. By targeting specific genetic markers, LP-184 could offer a more personalized treatment option for cancers that are often difficult to treat. The implications extend beyond Lantern Pharma, as this approach demonstrates the potential of integrating artificial intelligence into drug development to identify patient populations most likely to respond to a therapy.
For more details, the full press release is available at https://ibn.fm/LRGUo. Lantern Pharma is a clinical-stage precision oncology company leveraging AI, machine learning, and its proprietary RADR platform to transform the development of cancer therapies. The company’s clinical pipeline includes LP-184, LP-284, and LP-300, with LP-184 also being developed for pediatric CNS cancers through Starlight Therapeutics. Additionally, withZeta.ai, Lantern’s multi-agentic AI co-scientist platform, is now commercially available as a subscription-based research platform, representing a new revenue stream for the Company.
